Literature DB >> 28651958

Conception by means of in vitro fertilization is not associated with maternal depressive symptoms during pregnancy or postpartum.

Pietro Gambadauro1, Stavros Iliadis2, Emma Bränn2, Alkistis Skalkidou2.   

Abstract

OBJECTIVE: To study whether conception by means of in vitro fertilization (IVF) is associated with maternal depressive symptoms during pregnancy or postpartum.
DESIGN: Longitudinal observational study.
SETTING: University hospital. PATIENT(S): A total of 3,283 women with singleton pregnancies receiving antenatal care and delivering in Uppsala from 2010 to 2015. INTERVENTION(S): A web-based self-administered structured questionnaire including sociodemographic, clinical and pregnancy-related items, and the Edinburgh Postnatal Depression Scale (EPDS) was delivered at 17 and 32 gestational weeks and at 6 weeks and 6 months postpartum. MAIN OUTCOME MEASURE(S): Prevalence of significant depressive symptoms (EPDS ≥12) and EPDS scores. RESULT(S): A total of 167 women (5%) had conceived via IVF and 3,116 (95%) had a spontaneous pregnancy. IVF mothers were more frequently ≥35 years of age (46.1% vs. 22.6%) and primiparous (71.7% vs. 49.9%) and had a higher cesarean delivery rate (22.4% vs. 14.2%). Demographic and clinical characteristics were otherwise similar between the two groups. Significant depressive symptoms were reported by 12.8%, 12.4%, 13.8%, and 11.9% of women at 17 and 32 gestational weeks and 6 weeks and 6 months postpartum, respectively. The prevalence of depressive symptoms and the EPDS scores during pregnancy and postpartum were similar between women conceiving spontaneously or through IVF. The mode of conception was not associated with significant depressive symptoms at any time point, even when adjusting for several possible confounders in multivariable logistic regression analysis. CONCLUSION(S): Despite the psychologic distress characterizing subfertility and its treatment, conception by means of IVF is not associated with maternal depressive symptoms during pregnancy or postpartum.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  In vitro fertilization; assisted reproductive technologies; depression; postpartum depression; pregnancy complications

Mesh:

Year:  2017        PMID: 28651958     DOI: 10.1016/j.fertnstert.2017.06.006

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  5 in total

Review 1.  Progesterone, reproduction, and psychiatric illness.

Authors:  Lindsay R Standeven; Katherine O McEvoy; Lauren M Osborne
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2020-06-18       Impact factor: 5.237

2.  Trajectories of Maternal Postpartum Depressive Symptoms.

Authors:  Diane L Putnick; Rajeshwari Sundaram; Erin M Bell; Akhgar Ghassabian; Risë B Goldstein; Sonia L Robinson; Yassaman Vafai; Stephen E Gilman; Edwina Yeung
Journal:  Pediatrics       Date:  2020-11       Impact factor: 7.124

3.  Cohort profile: the Biology, Affect, Stress, Imaging and Cognition (BASIC) study on perinatal depression in a population-based Swedish cohort.

Authors:  Cathrine Axfors; Emma Bränn; Hanna E Henriksson; Charlotte Hellgren; Theodora Kunovac Kallak; Emma Fransson; Susanne Lager; Stavros I Iliadis; Sara Sylvén; Fotios C Papadopoulos; Lisa Ekselius; Inger Sundström-Poromaa; Alkistis Skalkidou
Journal:  BMJ Open       Date:  2019-10-22       Impact factor: 2.692

4.  Does the Mode of Conception Influence Early Postpartum Depression? A Prospective Comparative Study from South India.

Authors:  Partheeban Muruganandam; Deepa Shanmugam; Niranjjan Ramachandran
Journal:  Indian J Psychol Med       Date:  2020-07-20

5.  Caesarean section in pregnancies conceived by assisted reproductive technology: a systematic review and meta-analysis.

Authors:  Nakeisha A Lodge-Tulloch; Flavia T S Elias; Jessica Pudwell; Laura Gaudet; Mark Walker; Graeme N Smith; Maria P Velez
Journal:  BMC Pregnancy Childbirth       Date:  2021-03-22       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.